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Abstract 
Background: Aerosol-mediated delivery of nano-based therapeutics to the lung has emerged as a 
promising alternative for treatment and prevention of lung diseases. Superparamagnetic iron 
oxide nanoparticles (SPIONs) have attracted significant attention for such applications due to 
their biocompatibility and magnetic properties. However, information is lacking about the 
characteristics of nebulized SPIONs for use as a therapeutic aerosol. To address this need, we 
conducted a physicochemical characterization of nebulized Rienso, a SPION-based formulation 
for intravenous treatment of anemia.  
 
Methods: Four different concentrations of SPION suspensions were nebulized with a 1-jet 
nebulizer. Particle size was measured in suspension by transmission electron microscopy (TEM), 
photon correlation spectroscopy (PCS) and nanoparticle tracking analysis (NTA); and in the 
aerosol by a scanning mobility particle sizer (SMPS).  
 
Results: The average particle size in suspension as measured by TEM, PCS and NTA was 9 ± 2 
nm, 27 ± 7 nm and 56 ± 10 nm, respectively. The particle size in suspension remained the same 
before and after the nebulization process. However, after aerosol collection in an impinger, the 
suspended particle size increased to 159 ± 46 nm as measured by NTA. The aerosol particle 
concentration increased linearly with increasing suspension concentration and the aerodynamic 
diameter remained relatively stable at around 75 nm as measured by SMPS. 
 
Conclusions: We demonstrated that the total number and particle size in the aerosol was 
modulated as a function of the initial concentration in the nebulizer. The data obtained marks the 
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first known independent characterization of nebulised Rienso and, as such, provides critical 
information on the behavior of Rienso nanoparticles in an aerosol. The data obtained in this 
study adds new knowledge for the existing body of literature on potential applications of SPION 
suspensions as inhaled aerosol therapeutics.  
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Introduction 
Engineered nanoparticles have gained increased attention for a number of biomedical and 
bioengineering applications. Namely, new applications of nanomaterials in the field of 
biomedicine have sparked significant interest as a route of therapeutic drug delivery to the lungs 
for both local and systemic treatments. The lungs represent an excellent entry portal for 
aerosolized nanoparticles due to their high surface area, thin epithelial barriers and extensive 
vasculature.1 Inhaled nanoparticles have been shown to deposit with high efficiency throughout 
the entire respiratory tract, from the extrapulmonary airways to the intrapulmonary regions, and 
subsequently undergo numerous transport processes within pulmonary tissues.2,3 An advantage 
of aerosolized nanoparticle formulations for pulmonary drug delivery is the fact that they 
demonstrate enhanced dispersion properties as particles with a diameter of <1µm are more easily 
incorporated in the respirable percentage of aerolized droplets.  Furthermore, certain 
biocompatible nanoparticles offer the potential for enhanced intracellular drug delivery.4  
Nevertheless, nanomedicine currently lacks information about the behaviour of certain nano-
based therapeutics once they are aerosolized for pulmonary delivery, including their 
agglomeration potential, deposited dose in the lung after inhalation and their subsequent fate in 
the human body. It is generally accepted that aerosol particles of 1-5µm are required for 
deposition in the alveolar region of the lung, where there is the highest systemic absorption. The 
primary factors influencing the aerosol particle size and the site of the aerosol deposition include 
the design of the inhalation device and the physicochemical properties of the drug formation.5 
However, the lack of characterization information for nebuilized nanotherapeutics marks an  
important research need in current nanomedicine efforts.  
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In this study, our interest was directed towards superparamagnetic iron oxide nanoparticles 
(SPIONs), which are synthetic γ-Fe2O3 (maghemite), Fe3O4 (magnetite) or α-Fe2O3 (hermatite) 
particles with a core ranging from 10 nm to 100 nm in diameter.6 In the last decade, biomedical 
interest for SPIONs has increased significantly due to a number of useful properties such as 
biocompatibility, biodegradability and superparamagnetism. Specifically, SPIONs offer a 
promising application for targeted imaging and treatment of lung cancer.7,8 In particular, a 
growing community of researchers have been investigating the potential for targeted aerosol 
delivery to specific lung regions using SPIONs in combination with a target-directed magnetic 
gradient fields.9,10 SPIONs can also serve as theranostic agents, i.e., both a diagnostic and 
therapeutic agents, where their inherent magnetic property can provide image contrast in 
magnetic resonance imaging (MRI) and thermal ablation in magnetic fluid hyperthermia (MFH) 
therapy.11  Moreover, as SPIONs can be chemically modified or engineered for simultaneous 
biomedical functions, their application as aerosolized chemotherapeutics may be used to increase 
drug dosage to the lungs while reducing systemic side effects.12 
Numerous preclinical and clinical studies have been conducted using SPIONs, resulting in their 
clinical approval for IV and oral administration.13,14,15,16  However, SPIONs have yet to be 
administered as pulmonary therapeutic agents for treatment and prevention of lung disease. A 
recent review article summarizing both human and animal in vivo inhalation data on iron oxide 
particles suggests that controlled human exposure to iron oxide nanoparticles, such as SPIONs, 
could be conducted safely, and as such, marks SPIONs as strong candidates for application as 
aerosol-mediated nano-therapeutics.17 Nevertheless, it should dually be noted that despite 
clinical approval of selected SPION formulations for IV and oral administration, certain animal 
studies have questioned the biocompatibility of SPIONs and their lack of cytotoxicity following 
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inhalation, specifically noting potential toxic effects due to macrophage clearance function 
overloading.18 To the authors’ knowledge, no controlled human inhalation studies have been 
carried out with aerosolized SPIONs, and as such, increased research is necessary to ascertain the 
biocompatibility of these nanoparticles before their application for human pulmonary use.   
Ferumoxytol (marketed under the names Feraheme (US) / Rienso (EU); referred throughout this 
article as Rienso) is an industrially synthesised SPION formulation used for the intravenous 
treatment of iron deficiency anaemia. As the only metal-based engineered nanoparticle approved 
by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), it 
serves as a preferred candidate for controlled human exposure studies.19 Ferumoxytol is coated 
with a polyglucose sorbitol carboxymethylether, which is designed to minimize immunological 
sensitivity and to isolate the bioactive iron from plasma components until the nanoparticle enters 
macrophages in the reticuloendothelial system of the liver, spleen, and bone marrow. The iron is 
then released intracellularly within vesicles in macrophages where it can bind to ferritin or 
incorporate into haemoglobin.20 While the physical, pharmaco-kinetic, and biologic properties of 
ferumoxytol in therapeutic trials have been reported for intravenous injection21, the authors are 
not aware of physicochemical characterization conducted on nebulized Rienso.  
 
Materials and Methods 
Nanoparticles  
Rienso (Takeda Pharmaceuticals, Lot: 32327) was purchased commercially from the University 
Hospital of Lausanne Pharmacy (Lausanne, Switzerland) in 17 ml glass vials. The manufacturer 
description describes Rienso as an aqueous colloidal solution consisting of non-stoichiometric 
magnetite (superparamagnetic iron oxide) coated with polyglucose sorbitol carboxymethylether, 
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with elemental iron concentration of 30 mg/ml, mannitol at concentration of 44 mg/ml, water, 
and sodium hydroxide and hydrochloric acid for pH adjustments.  The particle size was reported 
to be 17-30 nm and the molecular weight given was 731 kDa.  Upon receipt of the original vial, 
1 mL aliquots were prepared in sterilized glass crimp vials under sterile conditions.  The sterile 
aliquots were stored at the recommended temperature of 20 °C before use, and diluted for the 
nebulization experiments before the marked expiration date.  
Particle suspensions  
Four concentrations of Rienso suspensions were prepared for nebulization by diluting 167 µl, 
333 µl, 667 µl and 1333 µl of Rienso with 100 ml of GenPure water at room temperature to 
achieve suspension mass concentrations of 0.05 mg/ml, 0.1 mg/ml. 0.2 mg/ml and 0.4 mg/ml, 
respectively. Rienso solutions were nebulized immediately after preparation over a 40 minute 
period. Nebulization for each concentration was repeated three times. The suspension was 
characterized before and after the nebulization.  Four complimentary concentrations of mannitol 
(Rienso’s primary excipient) were prepared to achieve mass concentrations of 0.07 mg/ml, 0.15 
mg/ml, 0.29 mg/ml and 0.59 mg/ml. As Rienso contains 44 mg/ml of mannitol to 30 mg/ml Fe, it 
was deemed important to conduct separate mannitol nebulizations to deduce potential 
interactions between aerosolized SPIONs and mannitol particles.   
Nebulization system  
A custom nebulization system was used and consisted of a 1-jet Collison nebulizer (BGI 
Incorporated, USA), glass mixing tube (length of 53.5 cm and a diameter of 8.3 cm), and 
collection and measurement station. In this system (Figure 1), the Collison nebulizer was fed by 
a 50 litre cylinder of respirable air. A second airflow, technical air treated by a HEPA filter, led 
to the glass mixing tube in order to homogenize the two air flows and establish a stable humidity 
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level. The dry air was also used to dry the aerosol which allows for nanosized particles versus 
micron sized droplets to be measured.The aerosol was then directed to a collection and 
characterization station comprised of a scanning mobility particle sizer (SMPS: Grimm Ainring, 
Germany, models 55-40-25 (CPC) and 5.403 (DMA)) to characterize the particle size 
distribution/number concentration of the aerosol as well as an impinger to collect the aerosolized 
particles.  
The nebulizer was operated at 20  PSI with a flow rate of 2 l/min from the air cylinder. The 
Collison nebulizer generates an aerosol by aspirating the suspension through a sonic-velocity jet, 
thus shearing the liquid into droplets. The Collison nebulizer was selected for the Rienso 
aerosolization as this specific nebulizer represents a validated instrument in aerosol research, 
known for its reliable generation of constant aerosol concentrations over extended periods of 
time with little change in particle size distribution.22,23 According to the manufacturer, droplets 
produced have a mass median diameter of 2 µm at 20 psi and the liquid use rate of the nebulizer 
was 1.5 ml/hr. The second air flow to the mixing tube was set at a complimentary rate of 2 l/min 
in order to obtain an average humidity of 50% throughout the exposure system.  The mixing tube 
was then connected directly to the scanning mobility particle sizer (SMPS: Grimm Ainring, 
Germany, models 55-40-25 (CPC) and 5.403 (DMA) for the characterization of particle size 
distribution/number concentration of the aerosol or to the impinger (filled with 20ml of GenPure 
water and kept in ice). 
Conductive tubing (Milian SA, Switzerland) with an internal diameter of 8 mm was used with 
the shortest lengths possible to enhance particle transport and reduce particle loss to the tubing. 
A digital thermal mass flow meter and controller (Bronkhorst High Tech B V, E Flow, 
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Netherlands) and a battery powered thermal mass flow meters for gases (red-y compact meter, 
Germany) were added along the tubes of each air flow to ensure constant airflow. 
 
Physicochemical characterization of Rienso  
Particle concentration measurement methods  
Atomic Absorption Spectroscopy (AAS)  
Atomic absorption spectroscopy measurements were carried out with a VARIAN AA240Z 
Zeeman (Varian, Inc., USA). Sterile Rienso was acid digested using HNO3. The iron content was 
determined by redox titration as well as by photometric measurements. 
Magnetic susceptibility measurements (MSM) 
Magnetic susceptibility measurements were performed with a MS2G small sample sensor 
(Bartington Instrument, UK). Plotting the magnetic susceptibility as a function of the 
nanoparticle concentration shows a linear relationship. Magnetic susceptibility represents the 
degree of magnetization of materials in response to an applied magnetic field. For samples with 
constant volume, magnetic susceptibility increases with the magnetic nanoparticle 
concentrations, and MSM has shown to be a robust and quick method for detecting SPION 
concentration in suspensions.24 However, it should dually be noted that at low concentrations, 
magnetic susceptibility is also dependent on the particle aggregation in suspension and as such, 
MSM should be interpreted carefully, and in combination with complimentary methods, to 
predict SPION concentration.25 
Inductively coupled plasma optical emission spectroscopy (ICP-OES) and Inductively coupled 
plasma mass spectrometry (ICP-MS)  
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Spectrometry measurements were performed with an ICPE-9000 Multitype ICP Emission 
Spectrometer (Shimadzu, Japan) and an ELAN DRC II ICP mass spectrometer (PerkinElmer, 
USA). First, 100 µl of the sample was dissolved with 100 µl hydrochloric acid 6M and then 
diluted 26 times with deionised and filtered water. ICP-OES was used for higher concentrations 
(0.05 mg/ml-0.4 mg/ml) and ICP-MS was preferred for the small concentrations of iron obtained 
in the impinger. 
Scanning mobility particle sampler (SMPS) 
Aerodynamic diameter measurements were performed with a SMPS (Grimm Ainring, Germany, 
models 55-40-25 (CPC) and 5.403 (DMA)). An average of three measurements was calculated.  
Particle size measurement methods  
Photon correlation spectroscopy (PCS) measurements 
Light scattering measurements were carried out at 90° on a photon correlation spectrometer 
(Brookhaven Instruments Corporation, USA) equipped with a BI-90000AT digital 
autocorrelator. The CONTIN method was used for data processing. The theoretical refractive 
index of 2.42 of magnetite26 was used to calculate the number and volume weighted distribution 
from the raw intensity data. Viscosity, refractive index, and dielectric constant of pure water 
were used to characterize the solvent. Three measurements were taken for each sample and 
averaged.  
Nanoparticle tracking analysis (NTA) measurements  
Nanoparticle tracking analysis (NTA) measurements were performed with a Nanosight LM 
series (Nanosight Ltd., Wiltshire, UK). All suspensions were diluted 100 times with Genpure 
water (except for impinger collected suspensions). For all NTA assessments, an average of three 
measurements was calculated. 
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Transmission electron microscopy (TEM)  
A Phillips CM-20 microscope operating at 200 kV and Phillips CM-300 at 300 kV was used for 
high-resolution transmission electron microscopy. To assess the Rienso particles in solution, 
carbon-coated copper TEM grids were prepared by diluting Rienso 100 times in double-distilled, 
deionized water. This solution was then pipetted onto TEM grids and allowed to dry slowly 
overnight. To assess the Rienso particles in aerosol, carbon-coated copper TEM grids were 
secured in a Mini Particle sampler (INERIS, France) and attached within the nebulization 
system. A Rienso suspension at 0.1 mg/ml was prepared with GenPure water and nebulization in 
the system for 30 minutes at 6 L/min. The physical particle size distribution for both Rienso 
particles in suspension and in aerosol was estimated by measuring 100 particles at various 
magnifications.  Image processing of TEM micrographs was performed with ImageJ (National 
Institutes of Health, USA).  
Additional characterization measurement 
Zeta Potential  
The zeta potential of the suspension was obtained with a ZetaPals analyzer (Brookhaven 
Instruments Corporation, USA). Samples were diluted to 0.1 mg/ml with GenPure water and an 
average of three measurements was calculated.  
Bacterial sterility  
Rienso stock solution was aliquoted in sterile glass containers and smeared on Tryptic Soy Agar 
plates (Sigma-Aldrich, USA) once every 3 days for a total of four consecutive weeks. The 
smeared plates were incubated at 25 degrees Celsius. One blank and one positive control (Rienso 
+ mouth swab) was prepared on the first day of sterility testing. As the Rienso SPION is coated 
with polygluocose sorbitol carboxymethylether (PSC), a carbohydrate, and several aliquots were 
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obtained from each sterile Rienso container, it was deemed necessary to determine if the 
aliquoting technique introduced contamination into the sample.  
 
Results and Discussion  
Characterization of Rienso Stock Solution  
Prior to the nebulization experiments, the stock solution (Rienso, Takeda Pharmaceuticals, 
Switzerland, lot 32327) was characterized to confirm the manufacturer description. PCS was  
used to test the stability of the nanoparticles in water, Phosphate Buffered Saline (PBS) and 
Dulbecco's Modified Eagle Medium (DMEM) at 37°C. Over 44 hours, the mean hydrodynamic 
diameter was 22 ± 2 nm, 22 ± 2 nm and 23 ± 3 nm in all three solutions, demonstrating the 
stability of the original nanoparticle size in the various media. The stability of the particle size in 
suspension over time in various media denotes an important feature for future studies due to the 
ability to ensure standardized exposure parameters. To confirm Rienso concentration 
(manufacturer description: 30 mg/ml Fe), atomic absorption spectroscopy measurements were 
carried out and an iron concentration of 29.9 mg/ml Fe was determined.  In order to evaluate 
compatibility of Rienso as a test substance for potential application as therapeutic aerosol 
studies, the sterility of the stock solution was assessed. Bacterial growth was confirmed to be 
negative for Rienso aliquots for up to four weeks. Only the positive control (Rienso + mouth 
swab) yielded bacteria colonies from day 1. 
For the nebulization experiments, we will first describe the results of the characterized 
nanoparticles in the initial suspension before nebulization. These results will be compared to the 
suspension in the nebulizer after undergoing 40 minutes of nebulization, and the suspension re-
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collected in the impinger after nebulization. The characterization of the aerosolized particles will 
then be discussed.  
 
Characterization of Rienso in Suspension  
Analysis of transmission electron micrographs of Rienso suspension revealed the mean diameter 
number (dn)27 to be 9 ± 2 nm (Figure 2).  The TEM micrographs further demonstrate that the 
electron dense particles are approximately uniform in size.  
The four Rienso suspensions (0.05 mg/ml, 0.1 mg/ml, 0.2 mg/ml, 0.4 mg/ml) were characterized 
prior to nebulization. Nanosight Tracking Analysis  (NTA) demonstrated an average number 
weighted hydrodynamic diameter of 60 ± 8nm, 56 ± 1nm, 48 ± 4 nm, 60 ± 4 nm, respectively.  
Light scattering measurements conducted with PCS demonstrated a number weighted average 
diameter (dn) of 13 ± 5 nm, 27 ± 7 nm, 24 ± 3nm, and 21 ± 5nm respectively.  
After nebulization, the size of the nanoparticles remained similar to those of the initial four 
suspension with NTA measurements of 64 ± 1 nm, 52 ± 2 nm, 72 ± 7nm and 67 ± 3nm 
respectively. PCS measurements of the suspension after nebulization also demonstrated an 
overall stability of particle diameter (dn) with 17 ± 1 nm, 23 ± 2 nm, 23 ± 5nm and 24 ± 10 nm 
respectively for each concentration.  
Following nebulization, the aerosol was re-collected in the impinger and the particle sizes were 
measured with NTA, but not with PCS, as the concentration was in the µg/ml range and 
therefore too low to be measured with the latter. The impinger results demonstrated that the 
particle size increased considerably to 156 ± 56nm, 159 ± 46 nm, 124 ± 19nm and 103 ± 5 nm 
for each of the concentrations, respectively. These results suggest that the size of the particles did 
not vary in the nebulizer before and after nebulisation, but increased considerably due to the 
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most likely formation of agglomerates during resolubilization from an aerosol to a liquid.  The 
results further demonstrate that the initial concentration does not influence the hydrodynamic 
diameter of the particles measured in the impinger.  
It is important to note that the size discrepancy between the particle size measured with TEM, 
PCS and NTA results from the fact that while TEM examines individual core nanoparticles, PCS 
is an ensemble measurement that measures effective diameter based on light scattering. NTA on 
the other hand measures the effective diameter based on particles’ Brownian motion. In other 
words, TEM provides a mean diameter number measurement of primary particles, while PCS 
and NTA provide a hydrodynamic diameter measurement of primary aggregates.18 
The zeta potential of the Rienso nanoparticles was measured before and after nebulization at 
each concentration and demonstrated an insignificant change overall. Rienso nanopartices in the 
initial solution demonstrated -38 ± 6mV, -40 ± 3 mV, -42 ± 1mV, and -40 ± 1 mV at 0.05 mg/ml, 
0.1 mg/ml, 0.2 mg/ml, and 0.4 mg/ml, respectively. In the solutions after nebulization, Rienso 
nanoparticles demonstrated -44 ± 1 mV, -43 ± 3 mV, -46 ± 2 mV, and -42 ± 1 mV at 0.05 
mg/ml, 0.1 mg/ml, 0.2 mg/ml, and 0.4 mg/ml respectively. The zeta potential of the Rienso 
nanoparticles before and after nebulization demonstrate a minimal increase after collection in the 
impinger. We were unable to measure the charge distribution of the suspension obtained in the 
impinger due to the extremely low concentration of Rienso nanoparticles (µg/ml range). From 
these results, we may conclude that no trend was observed and that the zeta potential remained 
constant between the initial solution and the nebulized solution. It has been reported that 
negatively charged particles are retained in the lungs more efficiently than positively charged 
molecules, therefore the negative charge of the formulation throughout the nebulization process 
gives a potential advantage as a drug carrier.28 
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Concentration of Iron in Rienso suspension following nebulization 
The concentration of SPIONs was obtained from magnetic susceptibility measurements and from 
ICP-OES for the suspension before and after nebulization and ICP-MS for the suspension in the 
impinger (Figure 3). Overall, we observed a slight increase in concentration in the nebulizer after 
nebulization, which is explained by a loss of approximately 3ml of water during nebulization 
from the formation of droplets in the aerosol containing the Rienso particles.  The concentration 
of SPIONs in the impinger was very small compared to the initial SPION concentration. 
Nevertheless, the same trend is observed; as the initial concentration increases, the concentration 
tends to increase in the impinger. When comparing the results of the two methods, a slight 
difference is observed, which may be due to the fact that the concentration is at the limit of 
detection for the MS2G small sample sensor. It is likewise important to note that, the standard 
error observed with the MS2G small sample sensor is larger due to the higher detection limit, 
which is 2x10-6 SI (2 µgFe/ml) compared to the detection limit of the ICP-MS, of 1 ppt (1 
ngFe/L).The difference between ICP-MS and magnetic susceptibility measurements may also be 
due to particle aggregation occurring in suspension, thereby resulting in lower concentration 
values as measured by the MS2G small sample sensor. However, when interpreted together, 
these two complimentary methods confirm the presence of iron and therefore of SPIONs in the 
impinger due to the nebulization process.  
 
Characterization of Rienso suspension in the aerosol 
The total number of aerosolized particles and their aerodynamic diameter over the 40 minute 
nebulization was measured with the SMPS. For each of the four concentrations, a peak 
concentration at a reproducible particle size of about 70 nm was observed. The intensity of this 
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peak increased as the initial concentration increased from approximately 45,000 particles/cm3 at 
0.05 mg/ml to approximately 80,000 particles/cm3 at 0.4 mg/ml (Figure 4 and 5). This result 
demonstrates that the number of SPIONs in each droplet most likely increased as the initial 
concentration increased, resulting in an overall increase in the concentration of SPIONs in the 
aerosol.  
In addition to this, it is important to note that the total number of aerosolized particles and their 
aerodynamic diameter are reproducible for each concentration. This represents an important 
feature for future applications as these results demonstrate that the particle size and number 
distribution is directly correlated to the initial concentration of the Rienso suspension. The size 
of the particles in the aerosol tends to increase slightly as the initial concentration increases, 
which is most likely due to increased particle agglomeration in the aerosol due to a larger 
concentration of aerosolized particles overall (Figure 6). With a greater concentration of particles 
in the aerosol, the propensity for particle to particle attraction and agglomeration is increased 
when compared to lower concentrations. In this series of nebulizations, the particle size 
distribution demonstrates a plateau at approximately 75 nm. 
The general trend observed with the total number of particles over time is a sharp increase over 
the first 10 minutes up to a plateau point. This plateau point tends to increase as the initial 
concentration is increased due to a greater number of particles in the nebulized droplets. The 
total number of particles measured for each Rienso suspension concentration is plotted in Figure 
7. The total number of particles in the aerosol is doubled from 0.1 mg/ml with around 600,000 
particles/cm3 to 0.4 mg/ml with around 1,200,000 particles/cm3. 
The interaction of nanoparticles with lung cells depends on the size of the particles.29 An 
increase in the size of the particle due to agglomeration may promote their clearance via 
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macrophages and could greatly influence the location of drug release. This indicates that changes 
in the size of the aerosolized nanoparticles may affect the drug dose and release kinetics. 
Nevertheless, the particle agglomeration in this study remained below 100 nm, which suggests a 
effective deposition in the alveolar region of the lung. 
 
The primary excipient of Rienso, mannitol, was also nebulized at four complimentary 
concentrations to the Rienso solutions in order to characterize its aerodynamic diameter and 
concentration in aerosol form. The series of mannitol nebulizations, when compared with the 
Rienso nebulizations, reveals two important observations. First, the total concentration of 
aerosolized particles was similar to the Rienso formulation (Figure 7), albeit slightly higher. 
Secondly, the aerodynamic diameter of the particles was smaller, in the range of 35-45 nm 
(Figure 6) compared with Rienso in the range of 60-70 nm. Several studies have highlighted the 
advantages of utilizing mannitol in aerosolized therapeutics formulations.30,31 The desirability of 
utilizing nebulized mannitol is largely a result of its minimal airway transepithelial permeability, 
resulting in a longer duration of therapeutic action, as well as its pleasant taste and mouth feel for 
encouraging patient use.32,33 
Aerosolized Rienso particles were also captured on a TEM grid and analyzed to compare with 
the Rienso particles in the suspension. Image analysis of aerosolized Rienso particles by TEM 
demonstrated an overall pattern of monodispersed spherical particles, comprised of agglomerates 
of primary particles (Figures 8a and 8b). In Figure 8b, a total of 32 primary particles which 
comprise Cluster A were analyzed and were determined to have an average diameter of 9± 2  
nm. A total of 20 primary particles that comprise Cluster B were also analyzed and were 
determined to have an average diameter of 8± 1 nm (Figure 8b). A full image analysis (ImageJ, 
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USA) of agglomerated particles in Figures 8a and 8b demonstrated a mean diameter of 
approximately 75 nm of each cluster (Figure 9). 
The ultimate aim of this study was to characterize ferumoxytol SPIONs before and after 
nebulization to deduce the effects of aerosolization of particle properties. While it was 
hypothesized that the change of state from suspension to aerosol would induce effects on the 
physical particle size, the question remained: how would the particles undergo alternations in this 
process specifically, and what would be their agglomeration behavior? By assessing the initial 
Rienso suspension, we demonstrated a primary particle mean diameter of approximately 9± 2 
nm, as measured by TEM analysis, which provides a value of the electron dense iron core. When 
measured by PCS, a measurement that takes into account hydrodynamic diameter of the colloidal 
particle, we observed a particle size that correlated with the manufacturer’s description of 17-30 
nm with an average hydrodynamic particle diameter of 25±3 nm.  Analysis of nebulized Rienso 
particles demonstrates clustering of primary particles and the formation of agglomerates that are 
in the approximate size range of the values collected by the SMPS. The formation of Rienso 
agglomerates in the aerosol can be explained by the inherent principles of nebulization. As the 
Rienso suspension is aspirated through the sonic-velocity jet, the liquid is sheared into droplets 
approximately 2 microns in size. Upon meeting the air, these droplets dry and evaporate, 
inducing the agglomeration of primary particles into larger clusters. This assertion is supported 
by the TEM micrographs before and after nebulization; the former demonstrating primary 
particle size of 9 nm, and the latter demonstrating 9 nm primary particles agglomerated into 
clusters approximately 75 nm in diameter. This observation directly correlates with aerosol data 
from the SMPS, which demonstrated an average aerodynamic particle diameter of approximately 
70-75 nm.  
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As the aerosol was re-condensed in the impinger, we observed a significant increase in particle 
diameter. As particle agglomerates in the aerosol are rehydrated in the impinger, it is possible 
that they are undergoing further agglomeration with proximal particles to form larger clusters. 
This assertion is supported by NTA data, which overall demonstrates a larger hydrodynamic 
particle diameter for particles recondensed in the impinger after undergoing nebulization 
compared to the particles before nebulization. This observation is critical for clinical therapeutic 
aerosol research as aerosolized particles that meet the air-liquid interface of the lungs will be 
resolubolized. Thus, understanding the kinetics of particle agglomeration and resulting particle 
size proves imperative for accurate estimation of targeted lung dose of aerosolized nanoparticles. 
Further research on aerosolized SPION characterization is needed to elucidate these preliminary 
observations.  
 
Conclusion 
In this article, we have used various characterization techniques to deduce the effects of 
nebulisation on the physical particle size and concentration of Rienso, a commercially available 
ferumoxytol SPION formulation. Overall, it was determined that the size of the nanoparticles in 
suspension did not change after nebulization, but did form agglomerates in the aerosol. The size 
and concentration of the particles in the aerosol tended to increase as the initial suspension 
concentration increased. The concentration of iron in the impinger after nebulization followed 
the same trend; with the SPION concentration in the impinger increasing as the initial 
concentration increased. To the authors’ knowledge, this study marks the first independent 
characterization of aerosolized Rienso and as such, provides critical information on the behavior 
of Rienso nanoparticles in an aerosol. The data obtained in this study adds new knowledge for 
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the existing body of literature on potential applications of ferumoxytol suspensions as inhaled 
aerosol therapeutics.  
 
Acknowledgements: 
The authors would like to thank the Swiss National Science Foundation, NRP 64 Project, Grant 
No. 406440_131282 for funding doctoral research of H.G. and the Whitaker International 
Program for funding the postdoctoral grant to N.L. The authors also thank Antonio Mucciolo, 
University of Lausanne, Switzerland, for assistance in TEM grid preparation and TEM sample 
analysis.  
 
Author Disclosure Statement: 
The authors declare that no conflicts of interest exist.  
 
 
 
 
 
 
 
 
References:  
20 
 
1 O'Hagan DT, Illum L: Absorption of peptides and proteins from the respiratory tract and the 
potential for development of locally administered vaccine. Crit. Rev. Ther. Drug Carr. 1990;7: 
35–97.  
2 Geiser M, Kreyling W: Deposition and biokinetics of inhaled nanoparticles. Particle and Fibre 
Toxicology, 2010;7:2. 
 
3 Kreyling WG, Möller W, Semmler-Behnke M, Oberdörster G: Particle dosimetry: deposition 
and clearance from the respiratory tract and translocation towards extra-pulmonary sites. 
Donaldson K, Borm P (eds). In Particle Toxicology. CRC Press, Taylor & Francis Croup. Boca 
Raton; Pp. 47-74, 2007. 
 
4 Bailey MM, Berkland CJ: Nanoparticle formulations in pulmonary drug delivery. Medicinal 
Research Reviews 2009;29(1):196-212. 
 
5 McCallion ON, Taylor KM, Thomas M, Taylor AJ: Nebulization of fluids of different 
physicochemical properties with air-jet and ultrasonic nebulizers. Pharm. Res.1995;12:149-164. 
 
6 Wahajuddin, Arora S: Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as 
drug carriers. International Journal of Nanomedicine 2012;7:3445-3471. 
 
7 Yoo MK, Park IK, Lim HT, Lee SJ, Jiang HL, Kim YK, Choi YJ, Cho MH, Cho CS: Folate–
PEG–superparamagnetic iron oxide nanoparticles for lung cancer imaging. Acta Biomaterialia 
2012;8(8):3005-3013. 
21 
 
                                                          
 8 Parcell KL, Kalber TL, Walker-Samuel S, Southern P, Pankhurst QA, Lythgoe MF, Janes SM: 
S89 Bimodal iron oxide nanoparticles for hyperthermia therapy and MR imaging in cancer. 
Thorax 2010;65(Suppl 4):A41-A42. 
 
9 Upadhyay D, Scalia S, Vogel R, Wheate N, Salama RO, Young PM, Traini D, Chrzanowski W:  
Magnetised Thermo Responsive Lipid Vehicles for Targeted and Controlled Lung Drug 
Delivery. Pharmaceutical Research 2012;29(9):2456-67. 
 
10 Tewes F, Ehrhardt C, Healy AM: Superparamagnetic iron oxide nanoparticles (SPIONs)-
loaded Trojan microparticles for targeted aerosol delivery to the lung. European Journal of 
Pharmaceutics and Biopharmaceutics 2013: In Press, Corrected Proof.  
11 Hofmann-Amtenbrink M, von Rechenberg B, Hofmann H: Superparamagnetic nanoparticles 
for biomedical applications. In: Nanostructured Materials for Biomedical Applications. Tan MC, 
Chow G, Ren L, (eds). Transworld Research Network. Kearala, India; Pp. 119-149, 2009.  
  
12 Verma NK, Crosbie-Staunton K, Satti A, Gallagher S, Ryan KB, Doody T, McAtamney C, 
MacLoughlin R, Galvin P, Burke CS, Volkov Y, Gun'ko YK: Magnetic core-shell nanoparticles 
for drug delivery by nebulization. Journal of Nanobiotechnology 2012;11(1):1. 
 
22 
 
                                                                                                                                                                                           
13 Bernd H, De Kerviler E, Gaillard S, Bonnemain B: Safety and tolerability of ultrasmall 
superparamagnetic iron oxide contrast agent: comprehensive analysis of a clinical development 
program. Invest Radiol 2009;44(6):336-342. 
 
14 Bourrinet P, Bengele H, Bonnemain B, Dencausse A, Idee JM, Jacobs PM, Lewis JM: 
Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall 
superparamagnetic iron oxide magnetic resonance contrast agent. Invest Radiol 2006;41(3):313-
324. 
 
15 Corot C, Robert P, Idee JM, Port M:  Recent advances in iron oxide nanocrystal technology for 
medical imaging. Adv Drug Deliv Rev 2006;58(14):1471-1504. 
 
16 Hahn P, Stark DD, Lewis JM, Saini S, Elizondo G, Weissleder R, Fretz CJ, Ferrucci JT: First 
clinical trial of a new superparamagnetic iron oxide for use as an oral gastrointestinal contrast 
agent in MR imaging. Radiology 1990;175(3):695-700. 
 
17 Lewinski N, Graczyk H, Riediker M: Human inhalation exposure to iron oxide particles. 
BioNanoMaterials 2013;14(1-2): 5-23, In Press. 
18 Zhu MT, Feng WY, Wang Y, Wang B, Wang M, Ouyang H, Zhao YL, Chai ZF: 
Particokinetics and extrapulmonary translocation of intratracheally instilled ferric oxide 
nanoparticles in rats and the potential health risk assessment. Toxicological Sciences 2009;107: 
342-351. 
 
23 
 
                                                                                                                                                                                           
19 Lu M, Cohen MH, Rieves D, Pazdur R: FDA report: Ferumoxytol for intravenous iron therapy 
in adult patients with chronic kidney disease. Am J Hematol 2010;85(5):315-319. 
 
20 Pai AB, Garba AO: Ferumoxytol: a silver lining in the treatment of chronic kidney disease or 
another dark cloud. J Blood Medicine 2012;3 77-85. 
 
21 Landry R, Jacobs PM, Davis R, Shenouda M, Bolton WK: Pharmacokinetic Study of 
Ferumoxytol: A New Iron Replacement Therapy in Normal Subjects and Hemodialysis Patients. 
Am J Nephrol 2005;25:400–410. 
 
22 May KR: The Collison Nebulizer. description, performance and application. Journal of 
Aerosol Science 1973;4(3):235. 
 
23 Gussman, RA: Note on the particle size output of collision nebulizers. Am Ind Hyg Assoc J 
1984;45(3):B8-B12. 
 
24 Maurizi L, Sakulkhu U, Gramoun A, Vallee JP, Hofmann H:  A fast and reproducible method 
to quantify magnetic nanoparticle biodistribution. Analyst 2014;139:1184.  
 
25 Hong CY,  Wu CC, Chiu YC, Yang SY, , Horng HE, Yang HC:  Magnetic susceptibility 
reduction method for magnetically labeled immunoassay. Appl. Phys. Lett. 2006;88:212512–
212513. 
 
24 
 
                                                                                                                                                                                           
26  Cornell RM, Schwertmann U: The Iron Oxides: Structures, Properties, Reactions, 
Occurrences and Uses. VCH Verlagsgesellshaft GMBH, Weinheim, Germany: pp. 533–559, 
1996. 
 
27 Bowen P: Particle Size Distribution Measurement From Millimeters to Nanometers and From 
Rods to Platelets. J Dispersion Science and Technology 2002;23(5):631-662.  
 
 
28 Fidler IJ, Raz A, Fogler WE, Kirsh R, Bugelski P, Poste G: Design of liposomes to improve 
delivery of macrophage-augmenting agents to alveolar macrophages. Cancer Research 
1980;40(12): 4460-4466. 
 
29 Griese M, Reinhardt D: Smaller sized particles are preferentially taken up by alveolartype II 
pneumocytes. J Drug Target 1998;5:471-479. 
 
30 Chan JG, Traini D, Chan HK, Young PM, Kwok PC: Delivery of high solubility polyols by 
vibrating mesh nebulizer to enhance mucociliary clearance. J Aerosol Med 2012;25(5): 297-305. 
 
31 Chan JG, Kwok PC, Young PM, Chan HK, Traini D: Mannitol delivered by vibrating mesh 
nebulisation for enhancing mucociliary clearance." J Pharmaceut Sci 2011;100(7):2693–2702. 
 
32 Daviskas E, Anderson SD, Jaques A, Charlton B: Inhaled mannitol improves the hydration and 
surface properties of sputum in patients with cystic fibrosis.  Chest 2010; 137(4): 861–868. 
25 
 
                                                                                                                                                                                           
 33 Minasian C, Wallis C, Metcalfe C, Bush A: Comparison of inhaled mannitol, daily rhDNase 
and a combination of both in children with cystic fibrosis: a randomised trial. Thorax 2010;65: 
51–56. 
 
 
 
Author of correspondence:  
Michael Riediker 
Institut de Santé au Travail 
Rte de la Corniche 2 
1066 Epalinges-Lausanne 
Switzerland 
Email : michael.riediker@hospvd.ch 
 
26 
 
                                                                                                                                                                                           
Graczyk - Characterization of Nebulized SPIONs - table 
Table  
Table 1: Properties of Rienso suspensions as measured by PCS, NTA and zeta potential before 
nebulization, after nebulization and after collection by impinger. 
 
Sample Concentration 
(mg/ml) 
PCS average 
number weighted 
size [nm] 
NTA average 
number weighted 
size [nm] 
Zeta Potential 
[mV] 
Before 
Nebulization 
0.05 
0.1 
0.2 
0.4 
13 ± 5  
27 ± 7 
24 ± 3  
21 ± 5 
60 ± 8 
56 ± 1 
48 ± 4 
60 ± 4 
-38 ± 1 
-40 ± 3 
-42 ± 1 
-40 ± 1 
After 
Nebulization 
0.05 17 ± 1 64 ± 1 -44 ± 1 
0.1 23 ± 2 52 ± 2 -43 ± 3 
0.2 23 ± 5 72 ± 7 -46 ± 2 
0.4 24 ± 10 67 ± 3 -42 ± 1 
Impinger 0.05 - 156 ± 56 - 
0.1 - 159 ± 46 - 
0.2 - 124 ± 19 - 
0.4 - 103 ± 5 - 
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Figure  1 
 
 
Set up of the nebulization system 
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Figure 2a (left) and 2b (right) 
 
 
 
 
High resolution transmission electron micrograph showing Rienso in the 10 nm range (Scale bar 
= 50 nm). 
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Figure 3 
 
 
 
Iron concentration in the impinger over the initial concentration measured with ICP-MS (blue) 
and magnetic susceptibility (red). 
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Figure 4 
 
 
 
 
Number of particles (Particle concentration) and particle size over time at 0.05 mg/ml as 
measured by the SMPS. 
 
 
 
 
 
 
 
 
 
 
 
10
:0
6 
10
:1
6 
10
:2
6 
10
:3
7 
10
:4
7 
10
:5
8 
11
:0
8 
0 
50000 
100000 
9.
79
 
13
.9
3 
19
.8
8 
28
.4
7 
41
.0
2 
59
.6
2 
87
.8
 
13
1.
96
 
20
4.
5 
33
1.
11
 
56
5.
67
 
N
um
be
r 
of
 p
ar
tic
le
s 
 (p
ar
tic
le
s/c
m
3 )
 
4 
 
Graczyk - Characterization of Nebulized SPIONs - figures 
 
Figure 5 
 
 
 
 
Number of particles (Particle concentration) and particle size over particle size at 0.4 mg/ml as 
measured by the SMPS. 
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Figure 6  
 
 
 
Size of the particles in the aerosol measured with the SMPS at 0.05 mg/ml, 0.1 mg/ml, 0.2 mg/ml, and 0.4 
mg/ml concentrations of Rienso (red) and Mannitol (blue). 
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Figure 7  
 
 
 
Total number of particles measured in the aerosol with the SMPS at 0.05 mg/ml, 0.1 mg/ml, 0.2 mg/ml, 
and 0.4 mg/ml concentrations of Rienso (red) and Mannitol (blue). 
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Figure 8a (left) and 8b (right) 
 
 
 
High resolution transmission electron micrograph of aerosolized Rienso collected on a TEM grid 
(Figure 8a on left: scale bar = 2 µm; figure 8b on right: scale bar = 200 nm).  
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Figure 9  
 
 
 
Histogram of ImageJ Analysis of Figures 8a and 8b demonstrating frequency distribution of size 
of agglomerated Rienso particles following nebulization. 
 
 
0 
5 
10 
15 
20 
25 
30 
35 
40 
25
 
10
0 
17
5 
25
0 
32
5 
40
0 
47
5 
55
0 
62
5 
70
0 
77
5 
85
0 
92
5 
10
00
 
10
75
 
11
50
 
12
25
 
13
00
 
13
75
 
14
50
 
15
25
 
16
00
 
16
75
 
Fr
eq
ue
nc
y 
Size (nm) 
9 
 
